The board of directors of CSPC Pharmaceutical Group Limited announced that the "Afatinib Dimaleate Tablets (20mg, 30mg, 40mg)" (the "Product") developed by CSPC Ouyi Pharmaceutical Co. Ltd., a subsidiary of the Company, has obtained drug registration approval granted by the National Medical Products Administration of the People's Republic of China, and is deemed to have passed the consistency of quality and efficacy evaluation of generic drugs. Afatinib dimaleate tablets are indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have sensitive epidermal growth factor receptor (EGFR) mutations and who have not received prior EGFR tyrosine kinase inhibitor (TKI) treatment; and treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) with disease progression during or after platinum-based chemotherapy. The approval of the Product further enriches the Group's product portfolio and enhances the Group's development in the oncology field.